Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Diagnostic Laboratory, |
RCV000239296 | SCV000297252 | uncertain significance | not specified | 2015-09-18 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000726281 | SCV000343442 | uncertain significance | not provided | 2018-01-22 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000726281 | SCV001151447 | uncertain significance | not provided | 2016-05-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001045423 | SCV001209273 | uncertain significance | Facioscapulohumeral muscular dystrophy 2 | 2025-01-13 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 88 of the SMCHD1 protein (p.Asp88Gly). This variant is present in population databases (rs200521548, gnomAD 0.06%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with fascioscapulohumeral muscular dystrophy (PMID: 31243061). ClinVar contains an entry for this variant (Variation ID: 252695). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Al Jalila Children’s Genomics Center, |
RCV000239296 | SCV001984434 | uncertain significance | not specified | 2020-08-17 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000726281 | SCV003821928 | uncertain significance | not provided | 2020-05-26 | criteria provided, single submitter | clinical testing |